COVID-19: AN INTRANASAL LENTIVIRAL VACCINE PROJECT PROVIDES IMPORTANT PROTECTION IN ANIMALS
Researchers from the Pasteur - TheraVectys joint laboratory have pre-published on BioRxiv the results of animal trials of a vaccine against COVID-19, using a lentiviral vector and administered intranasally. This study shows that the vaccine candidate induces very high antibody production, as well as an abundant cellular response and drastically reduces the viral load in the lungs. This work proves that an effective SARS-CoV-2 vaccine should make it possible to bring vaccine protection into the upper respiratory tract, at the gateway to the virus. Read full story here